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RESEARCH NOTE INFECTIOUS DISEASESSubcutaneously administered antibiotics: a
national survey of current practice from the
French Infectious Diseases (SPILF) and
Geriatric Medicine (SFGG) society networksE. Forestier1, M. Paccalin2, C. Roubaud-Baudron3, T. Fraisse4,
G. Gavazzi5 and J. Gaillat6
1) Service de Maladies Infectieuses, Centre Hospitalier, Chambéry, 2) Service
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Centre Hospitalier, Alès, 5) Service de Gériatrie, Centre Hospitalier
Universitaire, Grenoble and 6) Service de Maladies Infectieuses, Centre
Hospitalier, Annecy, FranceAbstractA national survey was performed to explore antibiotic prescription
by the subcutaneous (sc) route among French infectious diseases
and geriatric practitioners. Among the participating physicians,
367 (96.1%) declared administering sc antibiotics at some point.
Ceftriaxone was prescribed sc by all but one, and ertapenem,
teicoplanin, aminoglycosides and amoxicillin by 33.2%, 39.2%,
35.1% and 15.3%, respectively. The sc route was resorted to
mainly in case of unavailable oral, intravenous or intramuscular
routes, especially during palliative care. Pain, skin necrosis and
lack of efﬁcacy were the main adverse effects, reported by
70.8%, 12.8% and 19.9% of practitioners, respectively. Further
studies are needed to precise the indications, modalities and
tolerance of sc antibiotic use.
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p://dx.doi.org/10.1016/j.cmi.2014.11.017IntroductionSparse data have been published on the pharmacokinetics, ef-
ﬁcacy and tolerance of antibiotics administered subcutaneously
(sc) [1]. However, current practice among French physicians
seems to defy currently available evidence and guidelines. We
performed a survey among infectious diseases (ID) and geriatric
practitioners in France to estimate the frequency of sc antibi-
otic use as well as to explore which antibiotics are administered
sc, the clinical circumstances and the adverse effects of sc
administration.Materials and methodsAn online declaratory survey was conducted by the French ID
(SPILF) and geriatric (SFGG) society networks in April 2013. An
electronic questionnaire was mailed to the members of both
societies (approximately 600 (50% of clinicians) for the SPILF,
and 1200 (80% of clinicians) for the SFGG) regarding their sc
antibiotic prescription patterns. Participation was on a volun-
tary basis.ResultsThree hundred eighty-two practitioners ﬁlled in the survey (93
ID specialists, practicing in 51 acute medical wards, and 289
geriatricians working in 112 different institutions). Of these,
140 (48%) operated in short-stay geriatric units, and the others
worked in rehabilitation care centers, nursing homes and/or
long-term care facilities.
Three hundred sixty-seven practitioners (96.1%) declared
administering antibiotics sc at some point (Table 1). This
practice was more common in geriatricians (97.2%) compared
to ID specialists (92.5%). Geriatricians were more likely to treat
at least six patients per month by sc antibiotics (37% vs. 13.9%
of ID physicians). Forty geriatricians (14%) declared treating
more than ten patients per month by sc antibiotics. The
duration of sc antibiotics treatment was usually 4 to 14 days for
285 participants (77.5%), and sometimes more than 2 weeks for
45.3% of ID practitioners.
Ceftriaxone was the most prescribed antibiotic by the sc
route. A majority of ID physicians reported administering
ertapenem and teicoplanin by the sc route (70.9% and 80.2%
respectively). Sc aminoglycosides were mostly prescribed by
geriatricians (40.9%). Sc amoxicillin was used by 56 participants
(15.3%). Finally, some practitioners reported using sc cefepimeious Diseases. Published by Elsevier Ltd. All rights reserved
TABLE 1. Subcutaneous antibiotics prescription patterns of
French ID practitioners and geriatricians
Pattern
ID practitioners Geriatricians Total
(n [ 86) (n [ 281) (n[ 367)
No. of patients treated by sc antibiotics (per month)
<1 32 (37.2%) 30 (11%) 62 (16.9%)
1 to 5 41 (47.7%) 141 (50%) 182 (49.6%)
6 to 10 10 (11.6%) 65 (23%) 75 (20.4%)
>10 2 (2.3%) 40 (14%) 42 (11.4%)
DNP 1 (1.2%) 5 (2%) 6 (1.6%)
Duration of sc antibiotic treatment (days)
<4 3 (3.5%) 8 (3%) 1 (3%)
4 to 14 43 (50%) 242 (86%) 285 (77.5%)
>14 39 (45.3%) 30 (11%) 69 18.8%)
DNP 1 (1.2%) 1 (0%) 2 (0.5%)
Antibiotics used by sc route
Amoxicillin 8 (9.3%) 48 (17.1%) 56 (15.3%)
Aminoglycosides 14 (16.3%) 115 (40.9%) 129 (35.1%)
Ceftriaxone 85 (98.9%) 281 (100%) 366 (100%)
Ertapenem 61 (70.9%) 61 (21.7%) 122 (33.2%)
Teicoplanin 69 (80.2%) 75 (26.7%) 144 (39.2%)
Reason for resorting to sc route
Iv/im route contraindicated 85 (98.8%) 272 (96.8%) 357 (97.3%)
Oral route contraindicated 79 (91.9%) 273 (97.2%) 352 (95.9%)
Avoiding multiple
oral treatment
19 (22.1%) 141 (50.2%) 160 (43.6%)
Palliative care 68 (79.1%) 267 (95%) 335 (91.3%)
Facilitating hospital discharge 85 (94.2%) 170 (60.5%) 255 (69.5%)
Reason for not resorting to sc route
No pharmacokinetic
data published
48 (55.8%) 171 (60.9%) 219 (59.7%)
No marketing authorization 10 (11.6%) 97 (34.5%) 107 (29.2%)
Serum monitoring
not available
2 (2.3%) 9 (3.2%) 11 (3%)
No previous iv treatment 28 (32.6%) 25 (8.9%) 53 (14.4%)
Other 6 (7%) 6 (2.1%) 12 (3.3%)
DNP 17 (19.8%) 53 (18.9%) 70 (19.1%)
ID, infectious disease; DNP, did not pronounce; sc, subcutaneous; iv, intravenous;
im, intramuscular.
CMI Forestier et al. Subcutaneously administered antibiotics 370.e2(n = 9), imipenem (n = 6), piperacillin–tazobactam (n = 2),
amoxicillin-clavulanic acid (n = 2), ceftazidime (n = 1) and
doripenem (n = 1).
The main reason for resorting to the sc route was in the case
of unavailable oral, intravenous (iv) or intramuscular (im)
routes, especially during palliative care. Geriatricians were
more prone than ID physicians (50.2% vs. 22.1%) to prescribe
antibiotics sc to avoid oral polypharmacy. Conversely, 94.2% of
ID specialists vs. 60.2% of geriatricians reported using the sc
route to facilitate hospital discharge. Two hundred nineteen
practitioners (59.7%) declared that they do not prescribe an-
tibiotics sc in the absence of available pharmacokinetic and/or
clinical data. Unlike geriatricians (8.9%), ID specialists (32.6%)
were more prone to use the sc route only after an iv loading
dose. Conversely, 34.5% of geriatricians vs. 11.6% of ID phy-
sicians said they did not use the sc route in the absence of a
marketing authorization available for this route for a given
antibiotic. However, 43% of these practitioners used amoxi-
cillin, ertapenem and/or teicoplanin sc. The lack of serum
monitoring available for a molecule was an obstacle to use the
sc route for only 11 practitioners (3%). Other reasons reported
against sc route were treatment with a vitamin K antagonist,
edema, severe skin disease and severe sepsis.Clinical Microbiology and Infection © 2014 European Society of Clinical Microbiology and InPain was the main adverse effect reported with sc injection
of antibiotics. Two hundred twenty-ﬁve practitioners (61.3%)
reported that it occurred “sometimes” and 35 (9.5%) “often.”
Skin necrosis and lack of efﬁcacy were “sometimes” recorded,
respectively, by 47 (12.8%) and 73 (19.9%) prescribers of sc
antibiotics.DiscussionID physicians and geriatricians seem to routinely prescribe
antibiotics by the sc route in France. These results must be
carefully interpreted given the declaratory and voluntary nature
of our survey and the one quarter answer rate among the cli-
nicians from both societies. However, the participants worked
in more than 160 different hospitals throughout the French
territory, thus likely reﬂecting the current practice of a signif-
icant proportion of ID and geriatric physicians.
The sc route is frequently used to administer treatments
(hydration, midazolam, morphine succinate) in geriatric settings
because it is technically less time-consuming for nurses, painless
and safer to perform compared to iv and im injection, while
keeping the advantages of parenteral infusion [2,3]. Thus, sc
antibiotics are widely prescribed by French geriatricians
because the elderly often have poor venous access, contrain-
dications to the im route (notably anticoagulants) and unpre-
dictable oral intake and intestinal absorption, especially in
circumstances like palliative care. For ID physicians who deal
with infections requiring long-term parenteral treatment (such
as bone and joint infections or endocarditis) and multidrug-
resistant bacteria, the sc route allows extended parenteral
antibiotic treatment and early hospital discharge while avoiding
the infectious and thrombotic risks of a central venous access.
In addition, sc administration may well suit the pharmacody-
namics of time-dependent antibiotics (such as ertapenem and
teicoplanin), leading to more stable serum concentration over
24 hours.
However, sc antibiotics present numerous limitations which
may be insufﬁciently considered by physicians. Ceftriaxone has a
marketing authorization for that route, but published evidence
on its efﬁcacy and safety is limited [4–7]. Administering amino-
glycosides sc is formally contraindicated by recently published
French guidelines because of uncertain efﬁcacy and risk of skin
necrosis (http://ansm.sante.fr/Dossiers/Antibiotiques/Autres-
recommandations-impliquant-des-antibiotiques/(offset)/8). Data
on sc ertapenem and teicoplanin are promising but sparse
[8–12]. Several antibiotics, especially amoxicillin, are adminis-
tered by the sc route despite the absence of any published data.
Finally, adverse effects like skin necrosis and lack of efﬁcacy re-
ported in our survey could be serious.fectious Diseases. Published by Elsevier Ltd. All rights reserved, CMI, 21, 370.e1–370.e3
370.e3 Clinical Microbiology and Infection, Volume 21 Number 4, April 2015 CMIConclusionAdministering antibiotics via the sc route appears to be com-
mon among ID and geriatrics specialists in France, and it seems
to answer a real need in their daily practice. Given the absence
of any evidence on efﬁcacy and safety, this practice cannot be
recommended to date, and it should be deﬁnitively banned for
aminoglycosides. However, it may deserve further research for
time-dependent antibiotics because it could offer several ad-
vantages compared to other parenteral routes. An expert
group should be urgently created to review the evidence, make
clear national recommendations and plan further pharmacoki-
netic and clinical studies to validate (or not) this practice.Transparency declarationAll authors report no conﬂicts of interest relevant to this
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